FDA Proposed Rule to Significantly Reduce Nicotine in Tobacco Products

Dec.13.2024
FDA Proposed Rule to Significantly Reduce Nicotine in Tobacco Products
FDA proposes rule to drastically reduce nicotine in tobacco products as Biden administration nears end, aiming to reduce addiction.

According to a report by CNN on December 11th, the U.S. Food and Drug Administration (FDA) has submitted a proposed rule aimed at significantly reducing the nicotine content in tobacco products as the Biden administration's term comes to an end.


The FDA first hinted at its intention to limit nicotine content in 2018. In 2022, FDA Commissioner Dr. Robert Califf announced that the agency is developing a rule that would require tobacco companies to lower the nicotine content in cigarettes.


On Tuesday (10), the FDA submitted its proposal to the Office of Management and Budget. The FDA told CNN on Wednesday (11), "Establishing a maximum nicotine content standard to reduce the addictiveness of cigarettes and certain combustible tobacco products, when finalized, will be one of the most impactful actions in the history of tobacco product regulation in the United States.


The CEO of the American Lung Association, Harold Wimmer, expressed appreciation for the initiative.


Once this rule is finalized, it could change our country's efforts to eliminate tobacco use. Making tobacco products less addictive will greatly reduce the number of young people becoming addicted. Additionally, reducing the nicotine content in all commercial tobacco products, including e-cigarettes, is crucial.


Dr. Rose Marie Robertson, Deputy Chief Science and Medical Officer of the Heart Association, pointed out that even with restricted nicotine levels, not all smokers will quit as a result.


CNN has pointed out that the approval process may take several months, and the tobacco industry typically sues the government to prevent new regulations.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Reynolds American launches U.S. investment plan: to invest $3.2 billion to expand capacity and advance a shift toward smokeless products
Reynolds American launches U.S. investment plan: to invest $3.2 billion to expand capacity and advance a shift toward smokeless products
Reynolds American says it will invest more than $3.2 billion across its U.S. operations by 2030. The investment began in 2024 and is expected to support more than 2,000 direct and indirect jobs. The company says the plan covers modernization and expansion of manufacturing facilities, scaling innovation and production, supply-chain initiatives and employee training, and also references its R&D spending and related site footprint.
Mar.06 by 2FIRSTS.ai
Report: 43% of 546 Canadian specialty vape shops found non-compliant in federal inspections
Report: 43% of 546 Canadian specialty vape shops found non-compliant in federal inspections
Health Canada’s vaping compliance and enforcement report covering inspections from April 2024 to March 2025 found 43% of 546 specialty vaping businesses were not compliant with the Tobacco and Vaping Products Act and the Canada Consumer Product Safety Act, according to the report cited. Health inspectors seized vaping products at 235 specialty vaping establishments.
Feb.26 by 2FIRSTS.ai
Alaska AG warns 1,500+ retailers to stop selling unauthorized vapes and nicotine pouches
Alaska AG warns 1,500+ retailers to stop selling unauthorized vapes and nicotine pouches
Alaska’s attorney general has sent warning letters to more than 1,500 retailers and distributors, cautioning them against selling tobacco products — including e-cigarettes and oral nicotine pouches — that lack U.S. Food and Drug Administration authorization.
Mar.06 by 2FIRSTS.ai
Exclusive | China Starts Mandatory National Standards Process for Heated Cigarettes and Nicotine Pouches
Exclusive | China Starts Mandatory National Standards Process for Heated Cigarettes and Nicotine Pouches
China has launched mandatory national standards work for heated cigarettes and nicotine pouches, further formalizing regulation of both categories. The move may help lay groundwork for future market entry, but does not signal imminent domestic commercialization.
Apr.15
Virginia Restricts Vape Sales to Products Listed in State Directory From April 1
Virginia Restricts Vape Sales to Products Listed in State Directory From April 1
From April 1, vape shops in Virginia may sell only liquid nicotine and vapor products listed in the state directory. The Office of the Attorney General has recommended that commonwealth attorneys begin enforcing the 2024 law.
Apr.02 by 2FIRSTS.ai